Compare ABLV & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABLV | RNTX |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5M | 35.5M |
| IPO Year | N/A | N/A |
| Metric | ABLV | RNTX |
|---|---|---|
| Price | $0.67 | $1.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 24.8K | ★ 256.5K |
| Earning Date | 04-23-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $114,319,869.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.16 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $1.02 |
| 52 Week High | $1.77 | $3.50 |
| Indicator | ABLV | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.24 | 45.33 |
| Support Level | $0.63 | $1.21 |
| Resistance Level | $0.75 | $1.30 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 13.64 | 50.00 |
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.